focus -WSS

focus

author：entertainment 2025-09-30 21:22:21 - browse：74123

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Bird flu outbreak in cows is latest avian flu curveball

WSS

ASCO: AstraZeneca says CAR

Intellia reports positive results for its CRISPR

Diversity in clinical trials starts with building trust, experts say

Close Medicare's dangerous gaps in addiction treatment coverage

Key Senate committee drafts bipartisan bill to stem drug shortages

Cue Health's Covid

hotspot

focus

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

BMI, flaws aside, is found to be useful estimate of body fat in youth

George Santos makes 1st court appearance after pleading not guilty to 13 counts

MassMutual is introducing free genetic testing for members

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Woman returns to dialysis after doctors remove transplanted pig kidney

How to save PrEP access — and even expand it

MultiPlan and major insurers sued for alleged medical price

Heart attack and stroke risk calculators need revising

Element Biosciences CEO lays out genome sequencing strategy

focus

Let's speed up science by embracing open access publishing

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

MultiPlan and major insurers sued for alleged medical price

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Diversity in clinical trials starts with building trust, experts say

ASCO: Palliative care found as helpful given virtually as in person

explore

leisure time

hotspot

leisure time